{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T08:59:36Z","timestamp":1794646776112,"version":"4.9.1"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"15","license":[{"start":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T00:00:00Z","timestamp":1649980800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Although single-cytokine inhibitors can be considered in treating severe or refractory Beh\u00e7et disease (BD), these biologic agents are associated with potential therapeutic failure due to the multi-cytokine pathogenesis involving Th1- and Th17-type cytokines with activated Janus kinase\/signal transducer and activator of transcription signaling pathways. Notably, there is an increasing trend toward the use of small-molecule targeted drug tofacitinib (TOF), a pan-Janus kinase inhibitor, with immediate-release formulations for treating patients with severe or refractory systemic vasculitis involving different vessel sizes. Despite no reported efficacy of extended-release formulations in refractory BD yet, such a dosage form has pharmacokinetic parameters that are comparable to those of conventional immediate-release formulations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns and diagnosis:<\/jats:title>\n            <jats:p>We report the case of a 27-year-old local woman with recurrent manifestations of arthritis, orogential ulcerations, papulopustular lesions, and anterior uveitis. She was diagnosed with BD for more than 3 years, and received long-term corticosteroids plus immunosuppressants therapy with the complication of opportunistic candidiasis infection.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions and outcomes:<\/jats:title>\n            <jats:p>Under extended-release TOF 11\u200amg once-daily therapy, the patient achieved disease remission while sparing the use of corticosteroids during follow-up.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Our clinical observations implicate the oral convenience and therapeutic efficacy of extended-release TOF formulations in controlling the disease activity of BD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000029189","type":"journal-article","created":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T14:34:06Z","timestamp":1651070046000},"page":"e29189","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":15,"title":["Extended-release tofacitinib for refractory Beh\u00e7et disease"],"prefix":"10.1097","volume":"101","author":[{"given":"Chrong-Reen","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tak-Wah","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Dermatology, National Cheng Kung University Hospital, Tainan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Min","family":"Hsu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, National Cheng Kung University Hospital, Tainan, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,4,15]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41572-021-00301-1","article-title":"Beh\u00e7et syndrome","volume":"7","author":"Yazici","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","article-title":"2018 update of the EULAR recommendations for the management of Beh\u00e7et's syndrome","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40259-019-00333-w","article-title":"Selective JAKinibs: prospects in inflammatory and autoimmune diseases","volume":"33","author":"Virtanen A","year":"2019","journal-title":"BioDrugs"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","article-title":"Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach","volume":"18","author":"Tanaka","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1136\/annrheumdis-2016-209330","article-title":"Tofacitinib for polyarteritis nodosa: a tailored therapy","volume":"75","author":"Rimar","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1136\/annrheumdis-2020-217307","article-title":"A pilot study of tofacitinib for refractory Beh\u00e7et's syndrome","volume":"79","author":"Liu","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1136\/annrheumdis-2019-216606","article-title":"Successful remission with tofacitinib in a patient with refractory Takayasu arteritis complicated by ulcerative colitis","volume":"79","author":"Kuwabara","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1136\/annrheumdis-2021-220484","article-title":"Tofacitinib for the treatment of antineutrophil cytoplasm antibody-associated vasculitis: a pilot study","volume":"80","author":"Liu","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1002\/jcph.734","article-title":"Extended-release once-daily formulation of tofacitinib: evaluation of pharmacokinetics compared with immediate-release tofacitinib and impact of food","volume":"56","author":"Lamba","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"R11-20250504","first-page":"1078","article-title":"Criteria for diagnosis of Beh\u00e7et's disease. International Study Group for Beh\u00e7et's Disease","volume":"335","year":"1990","journal-title":"Lancet"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","article-title":"Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases","volume":"12","author":"Schwartz","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1002\/1529-0131(199909)42:9<1967::AID-ANR24>3.0.CO;2-Z","article-title":"Th1 polarization of the immune response in Behcet's disease","volume":"42","author":"Frassanito","year":"1999","journal-title":"Arthritis Rheum"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.jaci.2011.07.008","article-title":"Regulation of TH17 and regulatory T cells in patients with Behcet disease","volume":"128","author":"Direskeneli","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/gene.2014.64","article-title":"Activation of the JAK\/STAT pathway in Behcet's disease","volume":"16","author":"Tulunay","year":"2015","journal-title":"Genes Immun"},{"key":"R17-20250504","first-page":"01","article-title":"Gene expression profiling in Behcet's disease indicates an autoimmune component in the pathogenesis of the disease and opens new avenues for targeted therapy","volume":"2018","author":"Puccetti","year":"2018","journal-title":"J Immunol Res"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1093\/rheumatology\/kel329","article-title":"Autoimmunity vs autoinflammation in Behcet's disease: do we oversimplify a complex disorder?","volume":"45","author":"Direskeneli","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)","volume":"186","author":"Ghoreschi","year":"2011","journal-title":"J Immunol"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1080\/03009742.2021.1911054","article-title":"Extended-release tofacitinib improves refractory Takayasu's arteritis","volume":"51","author":"Wang","year":"2022","journal-title":"Scand J Rheumatol"},{"issue":"(Suppl 132)","key":"R21-20250504","doi-asserted-by":"crossref","first-page":"03","DOI":"10.55563\/clinexprheumatol\/lnvc9k","article-title":"One year in review 2021: Beh\u00e7et's syndrome","volume":"39","author":"Hatemi","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"R22-20250504","article-title":"Correspondence on \u2018A pilot study of tofacitinib for refractory Beh\u00e7et's syndrome\u2019","author":"Zou","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/cpt.576","article-title":"Model-informed development and registration of a once-daily regimen of extended-release tofacitinib","volume":"101","author":"Lamba","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"(Suppl 1)","key":"R24-20250504","doi-asserted-by":"crossref","first-page":"i17","DOI":"10.1093\/rheumatology\/key225","article-title":"Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis","volume":"58","author":"Taylor","year":"2019","journal-title":"Rheumatology (Oxford)"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000029189","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T03:07:20Z","timestamp":1746328040000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000029189"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2022,4,15]]},"references-count":24,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000029189","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,15]]},"assertion":[{"value":"2022-02-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}